Treating Alzheimer`s disease by targeting Amyloid ß-nitration
A novel treatment of Alzheimer´s disease based on an antibody against the NITRATED form of Amyloid-beta42, thus avoiding the side effects that have been observed in other approaches.
Specific early diagnosis of AD, Novel and specific approach for treating AD,
Antibody specific to nitrated Aβ for further clinical development
The invention offers a novel approach for an early diagnosis of AD. The invention also opens new avenues for developing either NCEs or biologicals interfering with the nitrated Aβ. Antibody-based therapeutic approaches (e.g. passive/active vaccination) are currently being developed. Prophylactic approaches are also conceivable
Part of the inflammatory response in Alzheimer´s disease (AD) is the upregulation of the inducible nitric oxide synthase NOS2 resulting in increased NO production. The invention is based on the finding that amyloid β (Aβ) is nitrated at tyrosine 10 in AD-brains. Nitration accelerates its aggregation and is present in Aβ plaques. Injection of the nitrated protein into the brain of APP/PS1 transgenic mice leads to β-amyloidosis. An antibody specific to the nitrated form of Aβ has been developed. A therapeutic approach interfering with the nitrated Aβ (rather than with the native Aβ-peptide) may provide a very specific treatment with a reduced risk of side-effects.
Licensing
12/07/2010 00:00:00
US201013383521 20100712
- international:
A01K67/027; A61K38/17; A61K39/395; A61K49/00; A61P25/28; C07K1/14; C07K16/28; G01N33/566
- cooperative:
C07K14/4711; C07K16/18; G01N33/6896; A61K2039/505; G01N2333/90254; G01N2800/2821
Patent application
2311
德國
